Esubond Injection (Ibandronate Sodium Hemihydrate)
Ibandronate Sodium Monohydrate 3.375mg
Injections · Prescription medication
Optus Pharmaceutical Co., Ltd.
MFDS item code 201306409 · Approved 2013.03.22 · Insurance code 674102111
Treatment of osteoporosis in postmenopausal women
This medication is used to treat osteoporosis that occurs in postmenopausal women. The decrease in female hormones due to menopause can weaken bones, and this helps prevent that and strengthen bones, reducing the risk of fractures. It helps improve bone density to maintain healthy bone status.
Administer 3mg by intravenous injection over 15 - 30 seconds once every 3 months. Patients should also take calcium and vitamin D. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible and continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment No dosage adjustment is required. Patients with renal impairment No dosage adjustment is required for patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or less or whose creatinine clearance is 30ml/min or greater. Since clinical experience is insufficient in patients whose serum creatinine exceeds 200 µmol/L(2.3mg/dL) or whose creatinine clearance is less than 30ml/min, administration of this medicine is not recommended. Elderly patients No dosage adjustment is required.
Efficacy and safety in children 18 years of age or younger have not been studied.
This medication must be administered intravenously, and care must be taken to avoid administration into an artery or around a vein, as it may cause tissue damage. It should not be used in patients with an allergy to this medication or its other components, or in those with untreated hypocalcemia. Gastrointestinal symptoms such as gastritis, diarrhea, abdominal pain, dyspepsia, nausea, and constipation may occur during the treatment. Musculoskeletal symptoms such as muscle pain, joint pain, and musculoskeletal pain may also be experienced, and some patients have reported neurological and skin adverse reactions such as headache or rash. Some patients may experience flu-like symptoms including fever, chills, fatigue, and muscle pain after administration of this medication, although these symptoms are usually temporary and mild. Calcium levels may temporarily decrease during the use of this medication, so hypocalcemia or metabolic bone and mineral disorders should be treated before administration, and adequate calcium and vitamin D intake is important. Patients receiving dental treatment are at risk of osteonecrosis of the jaw; therefore, it is advisable to have an oral examination before drug administration and to avoid excessive dental procedures during treatment. This medication can rarely cause serious adverse effects such as osteonecrosis of the jaw, external auditory canal osteonecrosis, severe allergic reactions, skin disorders, and atypical fractures. Particularly, if pain occurs in the thigh or groin area, the possibility of atypical fractures should be suspected and evaluated immediately. There is insufficient experience with the use of this medication in pregnant or breastfeeding women, and potential risks are known, so it is safer not to use it. For the elderly, dose adjustment is not necessary, but regular examination and check-ups are needed during treatment. In cases of overdose, effects on the kidneys and liver may occur, so careful monitoring is required, and electrolyte supplementation with calcium and magnesium may be necessary. This medication must not be mixed with calcium-containing solutions or other intravenous medications and should be diluted using solutions specifically for intravenous administration. Used needles and syringes should not be reused and should be disposed of safely.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air and moisture. It is advisable to maintain a storage temperature between 1 and 30 degrees Celsius to ensure the medication remains effective and prevents degradation.
This injection is a colorless and clear solution contained in a colorless and clear glass prefilled syringe with a single-use needle attached.
3 mL/prefilled syringe
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Ibandronate Sodium Monohydrate 3.375mg
Injections · Prescription medication
Optus Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Jeil Pharmaceutical Co., Ltd.
Ibandronate Sodium Monohydrate 3.375mg
Solution · Prescription medication
Jeil Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Chodang Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Ajou Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Aliko Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Teragen Etex Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.